SeqOnce Biosciences Inc

About:

Biotech - Life Science Tools and Diagnostics

Top Investors: Wavemaker 360, Embark Ventures, Mount Wilson Ventures

Description:

SeqOnce Biosciences is a biotechnology company focused on accelerating life sciences discoveries to improve the human condition from detecting pathogens to biomarkers associated with various diseases. The company’s efforts are focused on a broad range of genomic applications that include real-time PCR to next generation sequencing to new disruptive technologies with the goal of obtaining better results, faster. Founded in 2014, SeqOnce was spun out of USC and is privately held. The founders have complementary skill sets with CSO Joseph Dunham’s strong background in molecular biology and technology development and CEO Chris Angermayer’s expertise in finance and operations. SeqOnce is growing rapidly as it continues to launch new products in genomics, food safety, and pathogen detection.

Total Funding Amount:

$1.23M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Carlsbad, California, United States

Founded Date:

2014-02-04

Contact Email:

info(AT)seqonce.com

Founders:

Chris Angermayer, Joseph Dunham

Number of Employees:

11-50

Last Funding Date:

2018-10-26

IPO Status:

Private

Industries: